Mustang Bio Inc (MBIO) Stock Price, Quote & News

Company Profile

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases. It develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-101, an IL13Ra2 CAR T cell program for glioblastoma; and MB-108 for the treatment of herpes simplex virus-1 oncolytic virus C134. The company was incorporated in 201...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 652 4500

Website: www.mustangbio.com

Address:

95 Sawyer Road, Suite 110, Waltham, United States

SPYmyQQQ Oct. 2 at 1:07 PM

🎯 Target Hit 🏁 📨 From Oct 1, 2025 💊 $MBIO 💵 Entry: $1.5400 ✅ Exit: $1.6258 💰 P/L: +5.57% 👉 FREE TRIAL! spymyqqq/join/

0 · Reply

squiggleburp Sep. 30 at 10:19 PM

$MBIO This may be a sympathy play to $FBIO if they do receive an approval. Cheap shot to snag a win IF things line up. $DERM too

0 · Reply

WolfCola Sep. 29 at 5:00 PM

$FBIO what’s the story with $MBIO - Google says mbio is subsidiary of Fbio. And mbio has an orphan cancer drug in the works?

3 · Reply

SMM82 Sep. 26 at 3:40 PM

$MBIO This article from March 2024 still gives me some hope MBIO may show life at some point (or be an interesting acquisition target). That said, they still have a long road ahead and will require additional capital to continue on. https://www.cityofhope.org/city-of-hope-developed-chimeric-antigen-receptor-car-t-cell-therapy-shows-clinical-activity-in

0 · Reply

BigSqueezeComing Sep. 25 at 10:33 AM

$MBIO added to watchlist

0 · Reply

Father_Ice Sep. 20 at 11:45 PM

$YELLQ It's pretty crazy to think that the only stock recommendation I've been incorrect on in recent years was Mustang Bio. True, Rivian and JetBlu could do better...but the years in front of them still gives much time to improve. In the case of $MBIO, executives ruined everyone's positions which surprisingly include multiple Institutional investors! It's technically possible, but I no longer see them rebounding enough to make up for that heinous 50x reverse split decision.

1 · Reply

AlphaTauri Sep. 19 at 8:44 AM

$MBIO whatxis the next step/catalyst after this orphan drug designation grant ?

0 · Reply

Invest2live Sep. 18 at 4:59 PM

$MBIO anything below 2 is cheap; do your DD and get in. This has growth stability; has potential to win big.

0 · Reply

The_Gambl3r Sep. 17 at 5:46 PM

$MBIO

0 · Reply

AlSookTraders Sep. 17 at 5:17 PM

$MBIO keep an eye on this for volume, could send to 2+

0 · Reply

Dow Dips 1%; Mustang Bio Shares Spike Higher

Jul 7, 2025, 8:30 AM EDT - 3 months ago

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma

Mar 5, 2025, 4:15 PM EST - 7 months ago

Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement

FBIO

Feb 27, 2025, 4:05 PM EST - 7 months ago

Mustang Bio Announces Sale of Fixed Assets and Exit of Facility

Feb 11, 2025, 4:10 PM EST - 8 months ago

Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

Feb 10, 2025, 8:00 AM EST - 8 months ago

Mustang Bio Announces Closing of $8 Million Public Offering

Feb 6, 2025, 7:00 AM EST - 8 months ago

Mustang Bio Announces Pricing of $8 Million Public Offering

Jan 14, 2025, 8:00 AM EST - 9 months ago

Mustang Bio Announces Reverse Stock Split

Nov 12, 2024, 8:30 AM EST - 11 months ago

Mustang Bio Receives Positive Listing Determination from Nasdaq

Nov 7, 2024, 8:30 AM EST - 11 months ago

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma

Oct 24, 2024, 2:10 PM EDT - 1 year ago

Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds

Jun 28, 2024, 8:00 AM EDT - 1 year ago

Diamond Equity Research Releases Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB)

ENVB

Jun 21, 2024, 4:01 PM EDT - 1 year ago

Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 20, 2024, 8:00 AM EDT - 1 year ago

Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 18, 2024, 2:52 AM EDT - 1 year ago

Why are Mustang Bio shares (MBIO) up almost 500%?

Jun 17, 2024, 9:21 AM EDT - 1 year ago

Why Is Penny Stock Mustang Bio Trading Over 190% On Monday?

Jun 17, 2024, 8:30 AM EDT - 1 year ago

Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy

May 2, 2024, 4:01 PM EDT - 1 year ago

Mustang Bio Announces Closing of $4 Million Public Offering

Apr 29, 2024, 8:00 PM EDT - 1 year ago

Mustang Bio Announces Pricing of $4 Million Public Offering

Mar 28, 2024, 9:00 AM EDT - 1 year ago

Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases

Mar 11, 2024, 4:05 PM EDT - 1 year ago

Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

Mar 7, 2024, 7:30 AM EST - 1 year ago

Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma

Jan 11, 2024, 8:30 AM EST - 1 year ago

Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference

Dec 11, 2023, 8:30 AM EST - 1 year ago

Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting

Nov 14, 2023, 4:05 PM EST - 2 years ago

Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Nov 2, 2023, 9:28 AM EDT - 2 years ago

Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting

Oct 30, 2023, 2:15 PM EDT - 2 years ago

Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Oct 26, 2023, 12:30 PM EDT - 2 years ago

Mustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Oct 26, 2023, 9:00 AM EDT - 2 years ago

Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma

Sep 7, 2023, 8:15 AM EDT - 2 years ago

Mustang Bio to Participate in Upcoming September 2023 Investor Conferences

Aug 16, 2023, 8:00 AM EDT - 2 years ago

Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy

Aug 14, 2023, 4:05 PM EDT - 2 years ago

Mustang Bio Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

Aug 3, 2023, 8:00 AM EDT - 2 years ago

Mustang Bio to Participate in Two August 2023 Investor Conferences

Jul 31, 2023, 8:30 AM EDT - 2 years ago

Mustang Bio Announces Amendment and Closing of Strategic Manufacturing Partnership Transaction with uBriGene (Boston) Biosciences

Jul 6, 2023, 8:00 AM EDT - 2 years ago

Mustang Bio Announces Participation in Upcoming Scientific Meetings

Jun 15, 2023, 4:01 PM EDT - 2 years ago

Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy

Jun 12, 2023, 8:00 AM EDT - 2 years ago

Mustang Bio Announces Updated Results from Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy

May 18, 2023, 8:03 AM EDT - 2 years ago

Mustang Bio Announces Strategic Manufacturing Partnership and Portfolio Updates

May 12, 2023, 4:05 PM EDT - 2 years ago

Mustang Bio Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

May 11, 2023, 4:03 PM EDT - 2 years ago

Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy

Mar 29, 2023, 4:15 PM EDT - 2 years ago

Mustang Bio Reports Full-Year 2022 Financial Results and Recent Corporate Highlights

Mar 28, 2023, 8:30 AM EDT - 2 years ago

Mustang Bio to Participate in Cantor's The Future of Oncology Virtual Symposium

Jan 17, 2023, 8:15 AM EST - 2 years ago

Mustang Bio to Participate in the B. Riley Securities' 3rd Annual Oncology Conference

Dec 19, 2022, 8:30 AM EST - 3 years ago

Mustang Bio Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated Milestones

Nov 14, 2022, 4:05 PM EST - 3 years ago

Mustang Bio Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

Oct 27, 2022, 8:00 AM EDT - 3 years ago

Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th International Workshop for Waldenstrom's Macroglobulinemia

Oct 6, 2022, 8:30 AM EDT - 3 years ago

Mustang Bio Announces First Patient Treated in Its Multicenter Phase 1/2 Clinical Trial of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy to Treat B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Sep 23, 2022, 4:55 PM EDT - 3 years ago

Mustang Bio: This Horse May Gallop Still

Sep 8, 2022, 8:00 AM EDT - 3 years ago

Mustang Bio to Participate in Upcoming September 2022 Investor Conferences

Aug 11, 2022, 4:05 PM EDT - 3 years ago

Mustang Bio Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

SPYmyQQQ Oct. 2 at 1:07 PM

🎯 Target Hit 🏁 📨 From Oct 1, 2025 💊 $MBIO 💵 Entry: $1.5400 ✅ Exit: $1.6258 💰 P/L: +5.57% 👉 FREE TRIAL! spymyqqq/join/

0 · Reply

squiggleburp Sep. 30 at 10:19 PM

$MBIO This may be a sympathy play to $FBIO if they do receive an approval. Cheap shot to snag a win IF things line up. $DERM too

0 · Reply

WolfCola Sep. 29 at 5:00 PM

$FBIO what’s the story with $MBIO - Google says mbio is subsidiary of Fbio. And mbio has an orphan cancer drug in the works?

3 · Reply

SMM82 Sep. 26 at 3:40 PM

0 · Reply

BigSqueezeComing Sep. 25 at 10:33 AM

$MBIO added to watchlist

0 · Reply

Father_Ice Sep. 20 at 11:45 PM

1 · Reply

AlphaTauri Sep. 19 at 8:44 AM

$MBIO whatxis the next step/catalyst after this orphan drug designation grant ?

0 · Reply

Invest2live Sep. 18 at 4:59 PM

$MBIO anything below 2 is cheap; do your DD and get in. This has growth stability; has potential to win big.

0 · Reply

The_Gambl3r Sep. 17 at 5:46 PM

$MBIO

0 · Reply

AlSookTraders Sep. 17 at 5:17 PM

$MBIO keep an eye on this for volume, could send to 2+

0 · Reply

AuthenticLiving Sep. 12 at 4:26 PM

$MBIO not seeing any news on this. is it pumping with the market strength?

2 · Reply

bclund Sep. 11 at 8:28 PM

$MBIO The Lund Loop Daily Update: 09-11-2025 A review of today's action and a look at the profit opportunities for the next trading day. https://www.thelundloop.com/p/the-lund-loop-daily-update-09-11

0 · Reply

JoeyLatz Sep. 11 at 3:44 PM

$MBIO got this bullshit at 3$ a long way to recoup that. Hopefully this tea drinking clam chowder Massachusetts motherfuckas can turn this company around and get this stock to the moon

0 · Reply

FinSUN Sep. 11 at 2:46 PM

$MBIO

0 · Reply

SMM82 Sep. 11 at 2:32 PM

$MBIO May see a decent move today if breaks the $1.50 area w/ some volume.

0 · Reply

StockMasterCash Sep. 10 at 10:02 PM

$MBIO this is a sad sad sad story

0 · Reply

SEVENXStheGOAT Sep. 9 at 6:35 PM

$MBIO reloaded at 1.37 lets see

0 · Reply

SEVENXStheGOAT Sep. 8 at 6:26 PM

$MBIO been so quiet since June….

1 · Reply

QuantNut Sep. 8 at 1:46 PM

$MBIO

1 · Reply

NVDAMillionaire Sep. 4 at 9:12 PM

$MBIO Great piece that accurately captures MBIO's current position. So if you want to refresh your understanding of MBIO or learn about MBIO for the first time, this is essential reading. https://beyondspx.com/quote/MBIO/mustang-bio-a-high-stakes-pivot-in-cell-therapy-mbio#analysis

1 · Reply

Renato17 Aug. 28 at 12:53 PM

$FBIO $FBIOP $DERM $CKPT $MBIO

0 · Reply

Market Cap	11.44M
Revenue (ttm)	0.00
Net Income (ttm)	-15.75M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	64,100
Avg Vol	140,558
Day's Range	N/A - N/A
Shares Out	7.24M
Stochastic %K	60%
Beta	2.29
Analysts	Strong Buy
Price Target	$8.00